⌘K
Loading ticker…
As of 2026-08-21, Lexicon Pharmaceuticals, Inc. (LXRX) has a 3-month relative strength percentile of 54 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 63. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.8%, relative volume 1.10×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
LXRX is in a stage 2 uptrend, week 1. Currently in a 38-day base; basing ADR 6.3% (broad 6.6%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 0.8% / 31.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
LXRX is held by 4 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $2M notional. Top 3 carry $4M.
Held by 7 ETFs · $19M across latest filings · largest weight 0.60% (QQQS).
Top 4 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.01% | $1M | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $240K | — |
| QQQS | 0.60% | $114K | +0.12 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LXRX Jan avg: 10.69% median: 9.84% win: 100% σ: 10.67% n: 4 2022-04-12 → 2026-07-31 | LXRX Feb avg: 13.21% median: 13.58% win: 75% σ: 19.77% n: 4 2022-04-12 → 2026-07-31 | LXRX Mar avg: -5.90% median: 1.25% win: 50% σ: 19.49% n: 4 2022-04-12 → 2026-07-31 | LXRX Apr avg: -0.71% median: -1.65% win: 40% σ: 37.10% n: 5 2022-04-12 → 2026-07-31 | LXRX May avg: 13.48% median: 10.39% win: 60% σ: 22.97% n: 5 2022-04-12 → 2026-07-31 | LXRX Jun avg: 6.86% median: 5.08% win: 60% σ: 29.26% n: 5 2022-04-12 → 2026-07-31 | LXRX Jul avg: 11.81% median: 13.14% win: 60% σ: 19.82% n: 5 2022-04-12 → 2026-07-31 | LXRX Aug avg: -4.80% median: -5.81% win: 50% σ: 17.32% n: 4 2022-04-12 → 2026-07-31 (current) | LXRX Sep avg: -8.97% median: -10.99% win: 25% σ: 24.39% n: 4 2022-04-12 → 2026-07-31 | LXRX Oct avg: 7.44% median: 7.99% win: 75% σ: 14.91% n: 4 2022-04-12 → 2026-07-31 | LXRX Nov avg: -17.54% median: -7.49% win: 25% σ: 28.58% n: 4 2022-04-12 → 2026-07-31 | LXRX Dec avg: 1.47% median: -9.43% win: 25% σ: 28.99% n: 4 2022-04-12 → 2026-07-31 |